GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
GO:004603422 | Liver | HCC | ATP metabolic process | 198/7958 | 277/18723 | 8.30e-23 | 1.55e-20 | 198 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
GO:009719122 | Liver | HCC | extrinsic apoptotic signaling pathway | 143/7958 | 219/18723 | 6.99e-12 | 2.97e-10 | 143 |
GO:004346722 | Liver | HCC | regulation of generation of precursor metabolites and energy | 89/7958 | 130/18723 | 1.84e-09 | 5.35e-08 | 89 |
GO:005149522 | Liver | HCC | positive regulation of cytoskeleton organization | 138/7958 | 226/18723 | 1.26e-08 | 3.12e-07 | 138 |
GO:003253522 | Liver | HCC | regulation of cellular component size | 217/7958 | 383/18723 | 1.28e-08 | 3.14e-07 | 217 |
GO:000609022 | Liver | HCC | pyruvate metabolic process | 73/7958 | 106/18723 | 3.52e-08 | 7.82e-07 | 73 |
GO:001605222 | Liver | HCC | carbohydrate catabolic process | 99/7958 | 154/18723 | 3.79e-08 | 8.30e-07 | 99 |
GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
GO:000918522 | Liver | HCC | ribonucleoside diphosphate metabolic process | 72/7958 | 106/18723 | 1.05e-07 | 2.03e-06 | 72 |
GO:004603122 | Liver | HCC | ADP metabolic process | 63/7958 | 90/18723 | 1.17e-07 | 2.25e-06 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
P2RX7 | deletion | Frame_Shift_Del | novel | c.849_855delNNNNNNN | p.Asn284ProfsTer24 | p.N284Pfs*24 | Q99572 | protein_coding | | | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
P2RX7 | deletion | Frame_Shift_Del | novel | c.849_855delNNNNNNN | p.Asn284ProfsTer24 | p.N284Pfs*24 | Q99572 | protein_coding | | | TCGA-D1-A0ZP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
P2RX7 | SNV | Missense_Mutation | novel | c.1436N>A | p.Cys479Tyr | p.C479Y | Q99572 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-3K-AAZ8-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | PD |
P2RX7 | SNV | Missense_Mutation | | c.1520T>G | p.Ile507Ser | p.I507S | Q99572 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD |
P2RX7 | SNV | Missense_Mutation | | c.482N>A | p.Thr161Asn | p.T161N | Q99572 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
P2RX7 | SNV | Missense_Mutation | | c.1153N>T | p.Arg385Trp | p.R385W | Q99572 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-18-3416-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
P2RX7 | SNV | Missense_Mutation | novel | c.1545N>T | p.Lys515Asn | p.K515N | Q99572 | protein_coding | deleterious(0.02) | benign(0.255) | TCGA-22-5479-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | SD |
P2RX7 | SNV | Missense_Mutation | novel | c.547N>G | p.Asn183Asp | p.N183D | Q99572 | protein_coding | tolerated(0.24) | benign(0.062) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
P2RX7 | SNV | Missense_Mutation | | c.286N>A | p.Pro96Thr | p.P96T | Q99572 | protein_coding | deleterious(0) | possibly_damaging(0.783) | TCGA-46-3768-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD |
P2RX7 | SNV | Missense_Mutation | novel | c.1209N>G | p.Phe403Leu | p.F403L | Q99572 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-85-8048-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Pyridazinone derivative 1 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | CHEMBL3545206 | GSK1482160 | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | 387065584 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Thiazole-fused cycloalkyl carboxamide derivative 1 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Piperazine derivative 6 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Quinoline derivative 11 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | PMID27724045-Compound-15 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | allosteric modulator | 315661107 | | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL3545108 | AZD9056 | |
5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Quinoline derivative 10 | | |